Cargando…

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

Cytokines are potent immune modulating agents but are not ideal medicines in their natural form due to their short half-life and pleiotropic systemic effects. NKTR-214 is a clinical-stage biologic that comprises interleukin-2 (IL2) protein bound by multiple releasable polyethylene glycol (PEG) chain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charych, Deborah, Khalili, Samira, Dixit, Vidula, Kirk, Peter, Chang, Thomas, Langowski, John, Rubas, Werner, Doberstein, Stephen K., Eldon, Michael, Hoch, Ute, Zalevsky, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497954/ https://www.ncbi.nlm.nih.gov/pubmed/28678791 http://dx.doi.org/10.1371/journal.pone.0179431

Ejemplares similares

Synergistic antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 when combined with anti-PD-1 in murine tumor models
por: Murali, Addepalli, et al.
Publicado: (2015)

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases
por: Dixit, Neha, et al.
Publicado: (2021)

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer
por: Walker, Joshua M, et al.
Publicado: (2020)

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development
por: Lee, Alex S., et al.
Publicado: (2021)

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
por: Hoch, Ute, et al.
Publicado: (2014)

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT
por: Rolig, Annah S, et al.
Publicado: (2022)

Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
por: Hennessy, Marlene, et al.
Publicado: (2020)

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
por: Miyazaki, Takahiro, et al.
Publicado: (2021)

SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain
por: Markman, John, et al.
Publicado: (2019)

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
por: Adkins, Chris E., et al.
Publicado: (2015)

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus
por: Fanton, Christie, et al.
Publicado: (2022)

Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
por: Webster, Lynn, et al.
Publicado: (2018)

NKTR-061 (inhaled amikacin) delivers high lung doses in mechanically ventilated patients with pneumonia and in healthy subjects
por: Eldon, M, et al.
Publicado: (2008)

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR
por: Moody, Gordon, et al.
Publicado: (2015)

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
por: Parisi, Giulia, et al.
Publicado: (2020)

Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
por: Henningfield, Jack E, et al.
Publicado: (2020)

Gene expression profile of human colorectal cancer identified NKTR as a biomarker for liver metastasis
por: Bai, Rui, et al.
Publicado: (2022)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist
por: He, Handan, et al.
Publicado: (2023)

ACT001 inhibits the proliferation of non‐small cell lung cancer cells by upregulating NKTR expression
por: Zhao, Min, et al.
Publicado: (2022)

Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS)
por: Gudin, Jeffrey, et al.
Publicado: (2020)

An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin
por: Leese, Philip T, et al.
Publicado: (2015)

Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics
por: Shoji, S, et al.
Publicado: (2017)

In Silico, In Vitro and In Vivo Pharmacodynamic Characterization of Novel Analgesic Drug Candidate Somatostatin SST(4) Receptor Agonists
por: Kántás, Boglárka, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
por: Younis, Islam R., et al.
Publicado: (2023)

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
por: Levy-Cooperman, N., et al.
Publicado: (2016)

Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia
por: Luyt, Charles-Edouard, et al.
Publicado: (2009)

Anti-fibrotic Potential of AT(2) Receptor Agonists
por: Wang, Yan, et al.
Publicado: (2017)

New MT(2) Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists
por: Boutin, Jean A., et al.
Publicado: (2017)

High epithelial lining fluid concentrations of NKTR-061 (inhaled amikacin) twice daily achieved in pneumonic portions of lung
por: Chastre, J, et al.
Publicado: (2008)

Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
por: Nagpal, Seema, et al.
Publicado: (2015)

Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
por: Fernandez, Rafael Alonso, et al.
Publicado: (2022)

Rational engineering of Fc/Fc receptor interactions to improve antibody potency
por: Doberstein, S, et al.
Publicado: (2003)

Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin
por: Seino, Y, et al.
Publicado: (2014)

Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists
por: Vasile, Silvana, et al.
Publicado: (2020)

Agonist-Directed Desensitization of the β(2)-Adrenergic Receptor
por: Goral, Vasiliy, et al.
Publicado: (2011)

Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB(2) Receptor
por: Taylor, Lewis, et al.
Publicado: (2015)

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB(2) receptor
por: Patel, Monica, et al.
Publicado: (2023)

Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
por: Yempala, Thirumal, et al.
Publicado: (2020)

Human Toll-Like Receptor 8-Selective Agonistic Activities in 1-Alkyl-1H-benzimidazol-2-amines
por: Beesu, Mallesh, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_33th7h6rc7d3leqfjfosnnq7gt